tiprankstipranks
Advertisement
Advertisement

EKF Diagnostics Secures Three-Year U.S. Hematology Deal with Blood Centers of America

Story Highlights
  • EKF Diagnostics signs a three-year hematology purchasing deal with Blood Centers of America.
  • The agreement strengthens EKF’s push to lead global point-of-care hematology testing, targeting U.S. blood banks.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
EKF Diagnostics Secures Three-Year U.S. Hematology Deal with Blood Centers of America

Meet Samuel – Your Personal Investing Prophet

An update from EKF Diagnostics Holdings ( (GB:EKF) ) is now available.

EKF Diagnostics Holdings has signed a three-year group purchasing agreement with Blood Centers of America, the largest U.S. blood supply network, covering its DiaSpect Tm hand-held hemoglobin analyzer, consumable cuvettes and the EKF Link IT connectivity license. The deal includes pricing, training and integration support, positioning EKF to deepen its presence in the U.S. blood bank market, which management views as a major addressable opportunity for its point-of-care hematology portfolio and a key milestone in its strategy to become the global leader in POC hematology testing.

The most recent analyst rating on (GB:EKF) stock is a Hold with a £26.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.

Spark’s Take on GB:EKF Stock

According to Spark, TipRanks’ AI Analyst, GB:EKF is a Neutral.

EKF Diagnostics Holdings receives a score of 67, driven by strong financial performance and a positive earnings call. The company’s robust balance sheet and improved profitability are significant strengths. However, technical indicators suggest potential bearish momentum, and the valuation is moderate. The positive outlook from the earnings call, including strategic growth plans and a share buyback program, enhances the overall score.

To see Spark’s full report on GB:EKF stock, click here.

More about EKF Diagnostics Holdings

EKF Diagnostics Holdings is an AIM-listed global diagnostics business focused on point-of-care analysers in hematology and diabetes, as well as life sciences services including specialist manufacture of enzymes and custom products for diagnostic, food and industrial applications. Headquartered near Cardiff, the company operates five manufacturing sites across the U.S. and Germany and sells into more than 120 countries worldwide.

Average Trading Volume: 259,863

Technical Sentiment Signal: Sell

Current Market Cap: £111.4M

See more insights into EKF stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1